CTCE-9908

CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells[1][2].

Product Specifications

CAS Number

[1030384-98-5]

UNSPSC

12352209

Target

CXCR

Type

Peptides

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ctce-9908.html

Purity

99.47

Solubility

H2O : 33.33 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC(CNC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N)=O)CCCCNC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC(CNC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=O

Molecular Formula

C86H147N27O23

Molecular Weight

1927.25

References & Citations

[1]Joseph Kwong, et al. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther. 2009 Jul;8 (7) :1893-905.|[2]Saima Hassan, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011 Jul 1;129 (1) :225-32.